Inflammatory Bowel Diseases
Conditions
Keywords
Inflammatory Bowel Diseases, HLA, Biological therapy
Brief summary
The investigators propose an observational study including patients with inflammatory bowel disease under biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23 (Ustekinumab), followed by an external Gastroenterology consultation at Centro Hospitalar Tondela-Viseu.
Interventions
GENETICHLA-DQA1*05 and DRB1
All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
Sponsors
Centro Hospitalar Tondela-Viseu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with the diagnosis of IBD (according to ECCO diagnosis criteria); * Adult patients (over 18 years); * Full capability of signing informed consent.
Exclusion criteria
* Patients who refuse to participate in the study; * Patients submitted to prior biological therapy (only for the IBD-naive group)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to biological therapy | 36 months | To assess whether the presence of the HLA-DQA1\*05 and HLA DRB1 alleles in patients with inflammatory bowel disease is associated with primary failure or loss of response to biological therapy with anti-TNF (Infliximab and Adalimumab), anti-integrin α₄β₇ (Vedolizumab) or anti-interleukin 12-23 (Ustekinumab). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of HLA-DQ1*05 and DRB1 | 36 months | To determine the prevalence of HLA-DQ1\*05 and DRB1 alleles in IBD population and to compare with a population of healthy blood donor patients. |
Countries
Portugal
Contacts
Primary ContactAna Catarina Carvalho, MD
Backup ContactPaula Ministro, MD
Outcome results
None listed